MHC cross-dressing in antigen presentation.


Journal

Advances in immunology
ISSN: 1557-8445
Titre abrégé: Adv Immunol
Pays: United States
ID NLM: 0370425

Informations de publication

Date de publication:
2023
Historique:
medline: 27 11 2023
pubmed: 24 11 2023
entrez: 23 11 2023
Statut: ppublish

Résumé

Dendritic cells (DCs) orchestrate T cell responses by presenting antigenic peptides on major histocompatibility complex (MHC) and providing costimulation and other instructive signals. Professional antigen presenting cells (APCs), including DCs, are uniquely capable of generating and presenting peptide antigens derived from exogenous proteins. In addition to these canonical cross-presentation and MHC-II presentation pathways, APCs can also display exogenous peptide/MHC (p/MHC) acquired from neighboring cells and extracellular vesicles (EVs). This process, known as MHC cross-dressing, has been implicated in the regulation of T cell responses in a variety of in vivo contexts, including allogeneic solid organ transplantation, tumors, and viral infection. Although the occurrence of MHC cross-dressing has been clearly demonstrated, the importance of this antigen presentation mechanism continues to be elucidated. The contribution of MHC cross-dressing to overall antigen presentation has been obfuscated by the fact that DCs express the same MHC alleles as all other cells in the host, making it difficult to distinguish p/MHC generated within the DC from p/MHC acquired from another cell. As a result, much of what is known about MHC cross-dressing comes from studies using allogeneic organ transplantation and bone marrow chimeric mice, though recent development of mice bearing conditional knockout MHC and β2-microglobulin alleles should facilitate substantial progress in the coming years. In this review, we highlight recent advances in our understanding of MHC cross-dressing and its role in activating T cell responses in various contexts, as well as the experimental insights into the mechanism by which it occurs.

Identifiants

pubmed: 37996206
pii: S0065-2776(23)00026-3
doi: 10.1016/bs.ai.2023.07.001
pii:
doi:

Substances chimiques

Histocompatibility Antigens 0
Antigens 0
Peptides 0
Histocompatibility Antigens Class I 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115-147

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Brendan W MacNabb (BW)

Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States. Electronic address: bmacnabb@caltech.edu.

Justin Kline (J)

Department of Medicine, Committee on Immunology, and Committee on Cancer Biology, University of Chicago, Chicago, IL, United States. Electronic address: jkline@medicine.bsd.uchicago.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH